3 Australian Growth Stocks With High Insider Ownership Worth Watching

US 10 year yields sit near multi month highs as investors react to stickier inflation expectations. Higher borrowing costs can make steady growth harder to find, which is why stocks from the Fast Growing Stocks With High Insider Ownership screener stand out. This article highlights three companies where insiders have meaningful skin in the game and analysts see room for further growth, so you can focus your research.

The three stocks below are just a starting sample, and the full screen surfaces 99 more companies with equally compelling stories that are not covered here. To identify and analyze those extra opportunities with strong growth and insider alignment, head straight into the Fast Growing Stocks With High Insider Ownership screener.

Predictive Discovery is a gold company focused on exploring and developing reserves in West Africa, led by its flagship Bankan Gold project in north east Guinea, which spans 356 square kilometers. The company is still pre revenue, so investors are mainly paying for future production potential and its resource and reserve base rather than current cash flows. Predictive Discovery is currently valued at about A$3.95b, which reflects the scale of its projects and development ambitions.

Investors looking at Predictive Discovery are being offered exposure to early stage growth potential alongside live production progress, with Kiniero and Nampala already pouring gold and Bankan moving through front end engineering and key contract awards. The investment case depends on timely permits at Bankan and Mansounia, disciplined use of debt funded spending and successful execution in higher risk jurisdictions in Guinea and Mali. The company’s current pre revenue status therefore captures only part of the overall picture for this A$3.95b business.

Predictive Discovery sits at an inflection point where early stage projects and a A$3.95b valuation can mask what really matters. Before you judge the upside or the risks, walk through the 2 key rewards and 3 important warning signs (2 are major!)

Build your own insider backed growth shortlist

Predictive Discovery and the two other stocks in this article all surfaced from a single Simply Wall St screener, which is where your own ideas can really start to compound. Use our flexible Screener to mix filters like valuation, growth, quality and risk, or jump straight into any of our curated Investing Ideas.

Telix Pharmaceuticals is a commercial stage biopharma company that develops and sells radiopharmaceuticals that help doctors both detect and treat cancers, with a focus on prostate, kidney and brain tumours. Most of its revenue currently comes from Precision Medicine imaging products, which generated about US$621.9 million, while Manufacturing Solutions contributed roughly US$245.1 million and Therapeutics about US$9.3 million, partly offset by inter segment eliminations. The company is valued at around A$5.7b.

Telix Pharmaceuticals sits at the intersection of approved cancer imaging products and a broad therapeutic pipeline. Many investors are watching it closely despite recent share price weakness and higher R&D spend. The core Illuccix and Gozellix imaging franchise is already generating hundreds of millions of US$ in annual revenue. Multiple Phase 3 trials, a new Melbourne manufacturing facility and a collaboration with Regeneron indicate ambitions that extend beyond diagnostics alone. At the same time, unprofitability, reliance on external funding, pricing pressure in PSMA imaging and regulatory overhangs such as the SEC subpoena and prior FDA letters mean the story is not straightforward. For investors who can handle those risks, Telix represents a mix of current cash flow and optionality that may warrant a closer look.

Telix Pharmaceuticals sits at the crossroads of strong imaging revenue and an ambitious cancer treatment pipeline that many investors may still be underpricing. Get the full story in the analyst forecasts for Telix Pharmaceuticals and see what could change first.

Lindian Resources is a Perth based explorer focused on rare earths, bauxite and gold, with its flagship Kangankunde Rare Earths project in Malawi and assets across Tanzania, Guinea and Singapore. The company is still pre revenue, so investors are mainly looking at the resource potential and development pipeline rather than current cash flows, and the stock is valued at about A$1.54b.

Lindian Resources may interest you if you want exposure to rare earths at an early stage, with Kangankunde moving toward planned first concentrate production in Q4 2026 and Lindian aiming to align that with initial processing at its SARECO facility in Kazakhstan. The company is currently loss making, heavily reliant on external borrowing and has a very inexperienced, non independent board, which raises governance and funding risks that cannot be ignored.

Lindian Resources sits at the crossroads of rare earth ambition and real execution risk, yet its A$1.54b valuation may not fully reflect that balance. Get the missing context in the 1 key reward and 3 important warning signs (2 are major!)

Seeking Fresh Alternatives Before Momentum Flies

Some of the most notable breakout stories can attract attention early, then fade as interest floods in. Review these fresh stock ideas before the broader crowd and consider them while they may still be less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com